Bayer to Cooperate With Schering-Plough on Sales in US, Japan
549338
Bayer AG, Germany&#39;s second-biggest drug and chemical maker, formed a marketing partnership with US rival Schering-Plough Corp.
725625
German chemicals and pharmaceuticals giant Bayer says it is still open to further acquisitions even though it was still in the process of integrating Berlin-based drug maker Schering which it recently acquired for close to 17 billion euros (22 billion dollars).
318406
Germany&#039;s Bayer AG  fell  short of the 95 percent stake it needs to start a squeeze out  of minority shareholders in drugmaker Schering AG, but still  plans to buy the rest of the shares, it said on Wednesday.
241106
Hoffman-La Roche Inc., the US prescription pharmaceuticals unit of Swiss drug maker Roche Group, said Thursday that it will jointly develop and market an asthma drug with biotechnology firm Protein Design Labs Inc.
421782
Cisco Systems of the US, a network equipment company, and computer maker Fujitsu of Japan have formed an alliance to increase Japanese sales.
419077
LONDON (CBS.MW) -- Bayer AG (DE:575200) (BAY) Monday said it has agreed to sell its plasma products business to NPS BioTherapeutics, Inc.
641779
Schering-Plough Corp.  on  Monday reported quarterly earnings far higher than Wall Street  expected, fueled by growing demand for its drugs against  cholesterol, arthritis, allergies and hepatitis C.
765962
By Kyodo News International, Tokyo  Sep. 7--TOKYO -- Otsuka Pharmaceutical Co. and Eiken Chemical Co. said  Thursday they have concluded a basic contract to cooperate in research and  development of clinical diagnostics and their sales.
348152
The German drug maker Bayer said its third-quarter profit fell 35 percent on costs related to its acquisition of a rival, Schering, but its performance still exceeded analystsÂ expectations. Bayer earned 320 million euros ($419 million) in the three months through September, down from 493 million euros a year earlier. Sales rose 26 percent, to 7.78 billion euros ($10.2 billion). The company, based in Leverkusen, said it booked special charges totaling 139 million euros ($182 million) in the quarter, with 106 million euros ($139 million) of that mostly attributable to the integration of its health care unit with Schering. Bayer bought Schering in June in a deal worth nearly 16.9 billion euros ($22 billion) to strengthen its health care business. The company said its health care unit was Âthe principal growth engine for BayerÂs business in the third quarter,Â with sales climbing 73 percent, to 3.48 billion euros ($4.56 billion).
227799
Drugmakers Merck & Co.  and Schering-Plough Corp.  reported second-quarter results that handily topped Wall Street expectations on Monday, helped by increased sales of the cholesterol-lowering drugs they co-market and other medicines.
575614
Merck and Schering report bad news, but how much will it affect sales?
281314
Bayer AG, the German drug and chemical company, has agreed to sell its plasma products business for $590 million in cash and stock to the private U.S. investment groups Cerberus Capital Management and Ampersand ...
274636
Merck and Schering-Plough get together again.
207285
Pfizer Inc. PFE.N has signed a deal  with Schering AG SCHG.DE granting it a worldwide license to  Schering's ADP receptor antagonist program, the U.S. drug maker  said on Wednesday.
205867
German drug maker Schering, recently acquired by pharmaceuticals and chemicals giant Bayer, has said that it was teaming up with British drug giant AstraZeneca to develop a new treatment against breast cancer.
26608
German and Swiss drug makers Schering and Novartis are developing a new anti-cancer drug with annual sales potential of up to two billion euros (2.7 billion dollars), Schering chief Hubertus Erlen said.
283066
Bayer, the German chemicals and pharmaceuticals specialist, plans to axe 1,000 jobs at its Berlin-based drug maker Schering, the daily Der Tagesspiegel reported in an advance copy of its Monday issue.